CPP
FLXN

Crow Point Partners’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Crow Point Partners’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-17,379
Closed -$242K – 155
2019
Q3 		$242K Hold
17,379
– – 0.04% 100
2019
Q2 		$214K Hold
17,379
– – 0.03% 104
2019
Q1 		$217K Buy
17,379
+2,384
+16% +$31.9K 0.04% 106
2018
Q4 		$178K Buy
+14,995
New +$235K 0.03% 111
2018
Q2 		– Sell
-1,297
Closed -$29K – 255
2018
Q1 		$29K Buy
+1,297
New +$31.7K 0.01% 229

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Crow Point Partners's FLXN Position: Q4 2019 in Review

Crow Point Partners sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2019, closing a stake of 17,379 shares — an estimated $242K sold.

Crow Point Partners first reported a position in FLXN in Q1 2018 and held it in 5 quarters. The position peaked at $242K in Q3 2019. 133 funds tracked by Wall St. Rank hold FLXN as of Q4 2019.

  • Crow Point Partners reported no remaining Flexion Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Crow Point Partners sold 17,379 Flexion Therapeutics, Inc. shares in Q4 2019, an estimated $242K.
  • Crow Point Partners first reported a position in Flexion Therapeutics, Inc. in Q1 2018 and held it in 5 quarters.
  • Crow Point Partners's Flexion Therapeutics, Inc. position peaked at $242K in Q3 2019.
  • 133 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2019.

Based on Crow Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.